We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 27, 2021

GLP1-Receptor Agonists vs SGLT2 Inhibitors for Reduction of CHD Risk

Diabetes Research and Clinical Practice


Additional Info

Diabetes Research and Clinical Practice
Decrease of Coronary Heart Disease Risk With GLP1-Receptor Agonists or SGLT2 Inhibitors Therapy in Patients With Type 2 Diabetes in Primary Cardiovascular Prevention: A 24 Months Follow-Up Study
Diabetes Res. Clin. Pract. 2021 Jan 28;[EPub Ahead of Print], L D'Onofrio, C Mignogna, A Carlone, E Bellizzi, M Di Guida, C Moretti, S Zampetti, G Leto, E Maddaloni, R Buzzetti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading